Table 2.
Characteristics of Studies in Which Participants Were Enrolled
| Category | Short title | Sponsor | Design | Phase | Brief summary |
|---|---|---|---|---|---|
| CCT | AALL1131 | Children's Oncology Group | Therapeutic randomized control trial | Phase 3 | Multistrata study for patients with newly diagnosed high-risk pre-B ALL. Randomization after initial course of induction chemotherapy based on response to chemotherapy |
| AGCT1531 | Children's Oncology Group | Active surveillance and therapeutic randomized control trial | Phase 3 | Study of active surveillance for patients with newly diagnosed low-risk germ cell tumors and a randomized control trial for patients with standard-risk germ cell tumors | |
| AAML1331 | Children's Oncology Group | Therapeutic nonrandomized control trial | Phase 3 | Study of patients with newly diagnosed standard and high-risk acute promyelocytic leukemia to determine standard of care treatment | |
| Biology, specimen procurement, or registry | Extra Bone Marrow | Investigator initiated | Observational cohort | N/A | Mechanism for collecting extra bone marrow for anticipated biology studies in patients with suspected leukemia |
| ALL08B1 | Children's Oncology Group | Observational cohort | N/A | International tumor registry to develop a risk-based classification system with patients with newly diagnosed ALL | |
| ACCRN07 | Children's Oncology Group | Observational cohort | N/A | International tumor registry study for Children's Oncology Group to collect information about children with cancer | |
| Quality of life or supportive care | IDEAL | Investigator initiated | Interventional cohort (nonrandomized) | N/A | Pilot study of exercise and dietary intervention to improve treatment response and reduce toxicity during Induction phase of treatment for ALL |
| Ped-PRO-CTCAE | Investigator initiated | Observational cohort | N/A | Development of patient-reported outcome measure | |
| Chemotherapy adherence and drug level monitoring | ALL Thiopurines | Investigator initiated | Observational cohort | N/A | Assessment of reported adherence to 6-mercaptopurine, drug levels, and outcomes |
CCT, cancer clinical trial; ALL, acute lymphoblastic leukemia; N/A, not applicable.